MedTrace Logo

A Study to Assess the Safety, Efficacy and Tolerability of AZD8233 Treatment in Participants With Hyperlipidaemia

NCT04964557 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 411

Last updated 2023-12-15

Study results available
· View outcomes & findings →

Summary

AZD8233 is a PCSK9-targeted ASO for the reduction of circulating levels of LDL-C. This study aims to evaluate safety, efficacy and tolerability of AZD8233.

Conditions

  • Hyperlipidaemia

Interventions

DRUG

AZD8233

PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.

DRUG

Placebo

Placebo solution

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-07
Primary Completion
2022-07-15
Completion
2022-07-15
FDA Drug
Yes

Countries

  • United States
  • Czechia
  • Denmark
  • Hungary
  • Netherlands
  • Poland
  • Slovakia
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04964557 on ClinicalTrials.gov